Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Acquisitions: 2010-2019

Historic Acquisitions for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Dec 2019 value amounting to $3.1 million.

  • Lineage Cell Therapeutics' Acquisitions was N/A to $3.1 million in Q1 2019 from the same period last year, while for Mar 2019 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2019, which is N/A change from last year.
  • Lineage Cell Therapeutics' Acquisitions amounted to $3.1 million in FY2019, which was up 966.05% from $292,387 recorded in FY2012.
  • In the past 5 years, Lineage Cell Therapeutics' Acquisitions registered a high of $3.1 million during FY2019, and its lowest value of $3.1 million during FY2019.
  • For the 1-year period, Lineage Cell Therapeutics' Acquisitions averaged around $3.1 million, with its median value being $3.1 million (2019).